| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID6189: Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) |
| Formulation | intravenous infusion |
| Reference number | 5251 |
| Indication | Treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/03/2023 |
| NICE guidance | |